1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 High-profit margins
4.1.2 Huge market demand
4.1.3 Ability of Biopharmaceuticals to treat previously untreatable diseases
4.1.4 Increasing acceptance for Biopharmaceuticals
4.2 Restraints
4.2.1 Complicated and Cumbersome regulatory requirements
4.2.2 High-end manufacturing requirements
4.2.3 Increasing demand for affordable Biopharmaceuticals
4.3 Opportunities
4.3.1 Finding ways of cost reduction
4.3.2 Patent expiry paving the way for Biosimilars
4.4 Challenges
4.4.1 Requirement of cold chain
4.4.2 Scalability limited by several out of hand factors
4.4.3 Extremely difficult development process
5. The Middle East & Africa Biopharmaceuticals Market - By Type
5.1 Monoclonal Antibodies
5.1.1 Anti-Cancer Monoclonal Antibodies
5.1.2 Anti-Inflammatory Monoclonal Antibodies
5.1.3 Other Monoclonal Antibodies
5.2 Recombinant Growth Factors
5.2.1 Erythropoietin
5.2.2 Granulocyte Colony Stimulating Factor
5.3 Purified Proteins
5.3.1 Leukemia Inhibitory Factor (LIF)
5.3.2 P53 Protein
5.3.3 P38 Protein
5.4 Recombinant Proteins
5.4.1 Serum Albumin
5.4.2 Amyloid Protein
5.4.3 Defensin
5.4.4 Cyclase
5.4.5 Caspase
5.4.6 Cathepsin
5.5 Recombinant Hormones
5.5.1 Recombinant Human Growth Hormone (HGH)
5.5.2 Recombinant Insulin
5.6 Synthetic Immunomodulators
5.6.1 Cytokines, Interferons, Interleukins
5.6.2 Tumor Necrosis Factor (TNF)
5.7 Vaccines
5.7.1 Recombinant Vaccines
5.7.1.1 Cancer Vaccines
5.7.1.2 Malaria Vaccine
5.7.1.3 Ebola Vaccine
5.7.1.4 Hepatitis-B Vaccine
5.7.1.5 Tetanus vaccine
5.7.1.6 Diphtheria Vaccine
5.7.1.7 Cholera Vaccine
5.7.2 Conventional Vaccines
5.7.2.1 Polio Vaccine
5.7.2.2 Pox Vaccine
5.8 Recombinant Enzymes
5.8.1 Enterokinase
5.8.2 Transferrin
5.9 Others
5.9.1 Blood factors
6. The Middle East & Africa Biopharmaceuticals Market- By Therapeutic Application
6.1 Oncology
6.1.2 Inflammatory and Infectious Diseases
6.1.3 Autoimmune Disorders
6.1.4 Metabolic Disorders
6.1.5 Hormonal Disorders
6.1.6 Disease Prevention
6.1.7 Cardiovascular Diseases
6.1.8 Neurological Diseases
6.1.9 Other Diseases
7. The Middle East & Africa Biopharmaceuticals Market- By Country
7.1.Introduction
7.2.Egypt
7.3. Africa
7.4. Rest of Middle East & Africa
8. Company Profiles
8.1 Merck & Co
8.2 F. Hoffmann-La Roche AG
8.3 Eli Lilly and Company
8.4 Sanofi
8.5 Amgen Inc.
8.6 AbbVie Inc.
8.7 Biogen Idec
8.8 Bayer AG
8.9 Johnson & Johnson
8.10 Pfizer, Inc
8.11 Novartis AG
9. The Middle East & Africa Biopharmaceuticals Market- Competitive Landscape
9.1 Market Share Analysis
9.2 Strategies Adopted by top companies
9.3 Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1 Insights of Industry Experts
10.2 Investment Opportunities
10.3 Analyst Opinion
11. Appendix
11.1 List of Tables
11.2 List of Figures
